Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hocanalyses of the EPOC trial

Peer Review reports

Original Submission
17 Jul 2014	Submitted	Original manuscript
22 Aug 2014	Reviewed	Reviewer Report - Tereza Gabelic
23 Aug 2014	Reviewed	Reviewer Report - Tomas Uher
6 Oct 2014	Author responded	Author comments - Luigi Barbato
Resubmission - Version 2
6 Oct 2014	Submitted	Manuscript version 2
28 Oct 2014	Author responded	Author comments - Luigi Barbato
Resubmission - Version 3
28 Oct 2014	Submitted	Manuscript version 3
Publishing
6 Nov 2014	Editorially accepted
26 Nov 2014	Article published	10.1186/s12883-014-0220-1

Back to article page